DENTSPLY SIRONA Inc

Análisis de la acción DENTSPLY SIRONA Inc (XRAY)

$8.440

-0.064 (-0.76%)Al cierre

Loading chart…
Máximo
8.575
Apertura
8.420
Precio medio ponderado por volumen
8.45
Volumen
3.97M
Capitalización
5.25B
Mínimo
8.325
Importe
33.52M
EV/EBITDA, TTM
5.52

DENTSPLY SIRONA Inc. is a diversified manufacturer of professional dental products and technologies. It develops, manufactures, and markets comprehensive solutions offering dental and oral health products, as well as other consumable medical devices. Its Connected Technology Solutions segment includes the design, manufacture and sales of its dental technology and equipment products. Its Essential Dental Solutions segment includes the development, manufacture and sales of the Company's value-added endodontic, restorative, and preventive consumable products and small equipment used by dental professionals for the treatment of patients. Its Orthodontic and Implant Solutions segment includes the design, manufacture, and sales of its various digital implant systems and dental implant products, digital dentures and digital orthodontic solutions. Its Wellspect Healthcare segment includes the design, manufacture, and sales of its continence care solutions for both urinary and bowel management.

Análisis de IA of DENTSPLY SIRONA Inc (XRAY)

Mantener

DENTSPLY SIRONA Inc (XRAY) is currently trading at $8.83, which is below the average analyst price target of $12. However, the stock has experienced a significant decline of 27.68% over the past year, indicating potential ongoing challenges. The RSI is at 44.98, suggesting it is nearing oversold territory, but not quite there yet. While the company has shown some improvement in gross margin to 54.90% in Q2 2026, the forward P/E ratio is 6.33, indicating it may be undervalued. The main risk is the ongoing revenue decline, which was reported at $898 million for Q2 2026, a 4.1% decrease year-over-year, reflecting challenges in market demand.

Recomendaciones de analistas (13)

+54.50% de potencial alcista
Comprar
8 Comprar
4 Mantener
1 Vender
Actual: 8.44
Mínimo
12.00
Promedio
13.04
Máximo
17.00

Piper Sandler

2026-10-09

Precio objetivo

$12

Neutral

BMO Capital

2026-09-17

Precio objetivo

$10

Market Perform

Barclays

2026-08-24

Precio objetivo

$11

Infraponderar

Barrington

2026-08-10

Precio objetivo

$15

Superar al mercado

BMO Capital

2026-08-07

Precio objetivo

$13

Market Perform

Métricas de valoración

El PER previsto actual de DENTSPLY SIRONA Inc (XRAY) es 6.33, frente a su media de 5 años de 13.79.

PER previsto

Infravalorado
Media 5A P/E
13.79
P/E actual
6.33
Sobrevalorada
19.29
Infravalorada
8.29

EV/EBITDA previsto

Valor razonable
Media 5A EV/EBITDA
5.05
EV/EBITDA actual
5.52
Sobrevalorada
31.43
Infravalorada
-21.33

Precio/ventas previsto

Infravalorado
Media 5A P/S
1.49
P/S actual
0.47
Sobrevalorada
2.20
Infravalorada
0.79

Escenarios de precio de Alphio AI para XRAY

Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.

A

Alcista

Alcista · 25%XRAY

$17.73

Precio del escenario

B

Base

Base · 50%XRAY

$16.62

Precio del escenario

B

Bajista

Bajista · 25%XRAY

$14.22

Precio del escenario

Ballenas con XRAY en cartera

E

Edmond de Rothschild Asset Management (France)

+ Con en carteraXRAY

+8.72%

Rentabilidad a 3 meses

S

Southpoint Capital Advisors LP

+ Con en carteraXRAY

+3.00%

Rentabilidad a 3 meses

C

Cooke & Bieler, L.P.

+ Con en carteraXRAY

-5.45%

Rentabilidad a 3 meses

A

Ariel Investments, LLC

+ Con en carteraXRAY

-5.64%

Rentabilidad a 3 meses

A

Armistice Capital LLC

+ Con en carteraXRAY

-7.87%

Rentabilidad a 3 meses

Cronología de eventos

2026-08-06 (ET)

16:30:00

Company Maintains FY26 Revenue Outlook of $3.5B-$3.6B

2026-07-28 (ET)

09:30:00

Dentsply Sirona Expands Partnership with Medline Sinclair

2026-06-11 (ET)

09:30:00

Dentsply Sirona Appoints John Fortson as CFO

2026-05-05 (ET)

16:20:00

Dentsply Sirona Reports Q1 Revenue of $880M

16:20:00

Company Maintains FY26 Revenue Outlook of $3.5B-$3.6B

Noticias

Preguntas frecuentes sobre XRAY, respondidas por Alphio AI

DENTSPLY SIRONA Inc. is a diversified manufacturer of professional dental products and technologies. It develops, manufactures, and markets comprehensive solutions offering dental and oral health products, as well as other consumable medical devices. Its Connected Technology Solutions segment includes the design, manufacture and sales of its dental technology and equipment products. Its Essential Dental Solutions segment includes the development, manufacture and sales of the Company's value-added endodontic, restorative, and preventive consumable products and small equipment used by dental professionals for the treatment of patients. Its Orthodontic and Implant Solutions segment includes the design, manufacture, and sales of its various digital implant systems and dental implant products, digital dentures and digital orthodontic solutions. Its Wellspect Healthcare segment includes the design, manufacture, and sales of its continence care solutions for both urinary and bowel management. It operates in the Healthcare sector (DENTAL EQUIPMENT & SUPPLIES industry).

DENTSPLY SIRONA Inc (XRAY) is currently trading at $8.83, which is below the average analyst price target of $12. However, the stock has experienced a significant decline of 27.68% over the past year, indicating potential ongoing challenges. The RSI is at 44.98, suggesting it is nearing oversold territory, but not quite there yet. While the company has shown some improvement in gross margin to 54.90% in Q2 2026, the forward P/E ratio is 6.33, indicating it may be undervalued. The main risk is the ongoing revenue decline, which was reported at $898 million for Q2 2026, a 4.1% decrease year-over-year, reflecting challenges in market demand.

13 analysts cover XRAY: 8 rate it Buy, 4 Hold and 1 Sell. The average price target is 13.04.

Comunidad

Más ↗

Aún no hay publicaciones

Regístrate o inicia sesión para participar

Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.

Empezar a operar